tbuckley/cabot-search huggingface dataset:
Computerized Capability of Office-Based Physicians to Identify Patients Who Need Preventive or Follow-up Care — United States, 2017
Authors: Damon F. Ogburn, Brian W. Ward, Alicia Ward
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Preventive care or follow-up care have the potential to improve health outcomes, reduce disease in the population, and decrease health care costs in the long-term (1). Approximately one half of persons in the United States receive general recommended preventive services (2,3). Missed physician appointments can hinder the receipt of needed health care (4). With electronic health record (EHR) systems able to improve interaction and communication between patients and providers (5), electronic reminders are used to decrease missed care. These reminders can improve various types of preventive and follow-up care, such as immunizations (6) and cancer screening (7); however, computerized capability must exist to make use of these reminders. To examine this capability among U.S. office-based physicians, data from the National Electronic Health Records Survey (NEHRS) for 2017, the most recent data available, were analyzed. An estimated 64.7% of office-based physicians had computerized capability to identify patients who were due for preventive or follow-up care, with 72.9% of primary care physicians and 71.4% of physicians with an EHR system having this capability compared with surgeons (54.8%), nonprimary care physicians (58.5%), and physicians without an EHR system (23.4%). Having an EHR system is associated with the ability to send electronic reminders to increase receipt of preventive or follow-up care, which has been shown to improve patient health outcomes (8).
Reconsidering Health Care Fraud and Abuse Laws
Authors: Carmel Shachar, Gregory Curfman
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT0218 Clinico-laboratory parallels between acute rheumatic fever and poststreptoccocal reactive arthritis
Authors: DM Dimov, None Zhutev, RD Raichev, RN Vacheva
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> In the last decades the interest in the problems of poststreptococcal reactive arthritis/PSReA/growed up caused by the increased number of publications on it. <h3>Objectives</h3> The aim of the work is to make comparison between acute rheumatic fever/ARF/and PSReA from the clinical and laboratory aspects. <h3>Methods</h3> Object of the investigation were 9 men aged 19,0 ± 1,0/18–21/fulfiled Jones criteria/1992/for ARF and 8 men and 2 woman aged 21,5 ± 5,6/18–32/fulfiling criteria of the Canadian Paediatric Society/1995/for PSReA. The patients were investigated and treated clinically and followed up till 60–90 th day. <h3>Results</h3> ARF developed more often after tonsillitis, PSreA – after catarrh of upper respiratory ways, the latent period being longer in ARF/20 ± 4,5 days/than in PSReA/11,8 ± 16,7 days/. The acute onset and fever were more characteristic of ARF than of PSReA. In ARF joint index was higher, joints were migratorily affected, the pain at rest was more violent, the leucocytes, ESR, AST-O and anti-DN-ase B showed higher values. In PSReA the joint affection was cumulative, the enthezopathies – more frequent and some morning stiffness existed. Auscultative finding and ECG changes were established only in ARF. After treatment beginning the joint syndrome in ARF was over in few days whereas in PSReA it persisted within a month. Normalisation of the laboratory changes occurred more slowly again in PSReA. <h3>Conclusion</h3> Despite of the same aetiology/antecedent streptococcal infection/the established clinical and laboratory features of ARF and PSReA permit to consider them as separate nosological units.
OrthoCARs: Engineered human IL-2/IL-2Rb orthogonal pairs selectively enhance CAR T cell antitumorefficacy
Authors: Paul-Joseph Aspuria, Michael A Bauer, Sandro vivona, Rene de Waal Malefyt, Rob Kastelein, Martin Oft, Jan Emmerich, Deepti Rokkam, Steven E Kauder, Scott McCauley, Romina Riener, Rakesh Verma
Journal: Blood (2020)
Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects
Authors: Giovanni Manfredi Assanto, Costantino Riemma, Francesco Malaspina, Salvatore Perrone, Maria Lucia De Luca, Giorgia Annechini, Gianna Maria D'elia, Maurizio Martelli, Robin Foà, Enrico Tiacci, Alessandro Pulsoni
Journal: Blood (2020)
Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial
Authors: Vincent Huberty, Ivo Boskoski, Vincenzo Bove, Pauline Van Ouytsel, Guido Costamagna, Marc A Barthet, Jacques Devière
Journal: Gut (2020)

Objective Endoscopic suture gastroplasty (ESG) has been developed as an alternative treatment for moderately obese patients. We present our results of a short-term randomised controlled trial on a new suturing technique, the Endomina system (E-ESG, Endo Tools therapeutics, Belgium). Design Eligible patients (body mass index 30–40 kg/m 2 ) were randomised in a 2:1 ratio to receive lifestyle modification plus E-ESG or lifestyle modification alone (control group); dietetic counselling and follow-up were identical. Endpoints included a mean excess weight loss (EWL) of more than 25% 12 months after E-ESG and a 15% EWL difference at 6 months between groups. At 6 months, a cross-over to E-ESG was offered to the control group. All patients were followed for a total of 12 months after E-ESG. Results Of the 71 patients included (five male, mean age 40 years), mean EWL at 6 months was significantly higher in the treatment (38.6%, n=45) than in the control group (13.4%, n=21; p&lt;0.001). At 6 months, satiety tests demonstrated a higher decrease in mean volume (41% vs 2.5%, p&lt;0.001), and mean quality of life (QoL) was also higher in the treatment group (52.8 vs 45.1 p&lt;0.05). No procedure-related or device-related severe adverse events were observed. Twelve months follow-up after E-ESG showed a mean EWL of 45.1%, which translated into a total body weight loss of 11.8%. Conclusions This study demonstrates that E-ESG is safe and effective, providing a 25% better EWL at 6 months than lifestyle modification alone. This weight loss was maintained and resulted in a significant improvement in QoL up to 18 months after treatment. Trial registration number NCT03255005 .
Sex Based Differences in Sickle Cell Disease
Authors: Rita V Masese, Dominique Bulgin, Mitchell Knisely, Liliana Preiss, Eleanor Stevenson, Jane S. Hankins, Marsha Treadwell, Allison A. King, Victor R. Gordeuk, Julie Kanter, Robert Gibson, Jeffrey A. Glassberg, Paula Tanabe, Nirmish Shah
Journal: Blood (2020)
Persistance of Inflammatory Phenotype of Neutrophils in Sickle Cell Disease Children Despite Chronic Exchange Transfusion Program: A Cause of the Progression of Cerebral Vasculopathy?
Authors: Abdoul Karim Dembele, Patricia Hermand-Tournamille, Florence Missud, Emmanuelle Lesprit, Malika Benkerrou, Yves Colin Aronovicz, Caroline Le Van Kim, Bérengère Koehl
Journal: Blood (2020)
Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)
Authors: Raffaele Palmieri, Alfonso Piciocchi, Valentina Arena, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Maria Irno Consalvo, Consuelo Conti, Cristina Attrotto, Daniela Fraboni, Maria Teresa Voso, William Arcese, Adriano Venditti, Francesco Buccisano
Journal: Blood (2020)
Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)
Authors: Jan A. Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A. Stevens, Sandra Dai, Leo W. K. Cheung, Kevin Kwei, Indu Lal, Emily Hsu, Thomas J. Kipps, Alessandra Tedeschi
Journal: Blood (2020)
Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
Authors: Julio C. Chavez, Caron A. Jacobson, Alison R. Sehgal, Sattva S. Neelapu, David G. Maloney, Gilles Salles, Basem M. William, Yin Yang, Lovely Goyal, Justin Chou, Vicki Plaks, Mauro P. Avanzi
Journal: Blood (2020)
Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)
Authors: Yaya Chu, Susiyan Jiang, Jian Jiang, Meijuan Tian, Dean Anthony Lee, Loui Madakamutil, Mario Q. Marcondes, Christian Klein, Mitchell S Cairo
Journal: Blood (2020)
Potent Interaction between CMV Reactivation and Gvhd: Immunologic Evidence for Blunting of CMV-Driven Immune Reconstitution in the Setting of Gvhd
Authors: Yvonne Suessmuth, Kayla Betz, Alison Yu, Brandi Bratrude, Benjamin Watkins, Muna Qayed, John T. Horan, Leslie Kean, Amelia Langston
Journal: Blood (2020)
Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease
Authors: Anna M Hood, Heather Strong, Cara Nwankwo, Yolanda Johnson, Constance A Mara, Lisa M Shook, William Brinkman, Francis J Real, Melissa Klein, Allison A. King, Cecelia Calhoun, Kim Smith-Whitley, Susan E Creary, Maria T Britto, Kay Linn Saving, Connie M. Piccone, Jean L. Raphael, Emmanuel Volanakis, Aimee K Hildenbrand, Steven K Reader, Sohail Rana, Lynne D. Neumayr, Amber M Yates, Sherif M. Badawy, Alexis A. Thompson, Amy Sobota, Emily Riehm Meier, Charles T. Quinn, Lori E. Crosby
Journal: Blood (2020)
Central Nervous System (CNS) Involvement in Adult Acute Lymphoblastic Leukemia (ALL) Assessed Solely By Flow Cytometry Has an Adverse Impact on Survival
Authors: Rosana Daniela Córdova-Serrano, Emmanuel Almanza Huante, Emmanuel Mártinez-Moreno, Areli Hérnandez-Alcántara, Emmanuel Fernández-Sánchez, Andres Gomez-De Leon, Karla Adriana Espinosa
Journal: Blood (2020)
Abstract 473: Induced Cardiomyocyte Cell Cycle After Myocardial Infarction Restarts the Neonatal Cardio-protective Signaling and Improves Wound Healing
Authors: Perwez Alam, Malina J Ivey, Shannon Jones, Yi-gang Wang, Sakthivel Sadayappan, Onur Kanisicak
Journal: Circulation Research (2020)

Background: Myocardial infarction leads to a massive loss of cardiomyocytes (CM) and cardiac remodeling, which results in reduced cardiac function and, ultimately, heart failure. Adult mammalian CMs cannot spontenously proliferate, and thus repair the cardiac injury, however in our previous study we showed that simultaneous knock down of Rb1 and Meis2 induced CM cell cycle activation that resulted in improved cardiac function. Moreover, most significant cardioprotective effects were due to CM mediated paracrine mechanisms including angiogenesis and CM cell survival. Thus, this study aims to identify these indirect cardioprotective pathways dependent on CM cell cycle. Methods and Results: We utilized genetically modified FUCCI mice, which allows identifying the cycling vs. non-cycling CM for transcriptome analysis. Adult mouse CM was isolated through the Langendorff heart perfusion method, using our modified isolation protocol, and cultured in the modified DMEM media. Adult CMs were transfected with equimolar (50uM each) combination of siRb1 and siMeis2 (siRNA-cocktail), cel-miR-67 served as control. CMs were harvested, and RNA isolation was performed on day seven after transfection. Rb1 and Meis2 knock-down were validated through CM proliferation analysis and RT-PCR based expression profiling for selected markers of proliferation, angiogenesis, cell survival, and structural genes. Our analysis showed a significant down-regulation of Rb1 and Meis2 after siRNA treatment.Further, we observed an up-regulation of pro-angiogenic and pro-survival genes without any significant alteration in the structural genes. After validating our samples, we performed a whole-genome transcriptome analysis using a high-throughput Illumina NextSeq platform. Our RNAseq analysis revealed the activation of pathways, which may induce the CM rejuvenation. The identified potential targets will be further validated through in vivo experiments. Conclusions: Our results suggest the activation of CM rejuvenation after knocking-down Rb1 and Meis2 to improve the cardioprotection after injury.
Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients
Authors: Alisa A. Mueller, Tomoyoshi Tamura, Conor P. Crowley, Jeremy R. DeGrado, Hibah Haider, Julia L. Jezmir, Gregory Keras, Erin H. Penn, Anthony F. Massaro, Edy Y. Kim
Journal: Cell Reports Medicine (2020)

In this single-center, retrospective cohort analysis of hospitalized coronavirus disease 2019 (COVID-19) patients, we investigate whether inflammatory biomarker levels predict respiratory decline in patients who initially present with stable disease. Examination of C-reactive protein (CRP) trends reveals that a rapid rise in CRP levels precedes respiratory deterioration and intubation, although CRP levels plateau in patients who remain stable. Increasing CRP during the first 48 h of hospitalization is a better predictor (with higher sensitivity) of respiratory decline than initial CRP levels or ROX indices (a physiological score of respiratory function). CRP, the proinflammatory cytokine interleukin-6 (IL-6), and physiological measures of hypoxemic respiratory failure are correlated, which suggests a mechanistic link. Our work shows that rising CRP predicts subsequent respiratory deterioration in COVID-19 and may suggest mechanistic insight and a potential role for targeted immunomodulation in a subset of patients early during hospitalization.
THU0171 A clinical relevant increase in radiological progression, the patient’s perspective
Authors: PM Welsing, AM Van Gestel, HL Swinkels, PL Van Riel
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Radiological progression is considered the most important outcome for Rheumatoid Arthritis, but there is no established definition, as to what constitutes a clinical important progression of joint damage. The smallest detectable difference (SDD) for the modified Sharp method and the Larson method was taken as a starting point. And expert opinion of rheumatologists was used to determine the clinical relevant progression. However these findings might not reflect the true clinical important progression in radiological damage. The clinical important difference should be the effect this progression has on the patient, being the development of physical disability. <h3>Objectives</h3> To estimate the clinical relevant increase in radiological damage, using the effect on physical disability. <h3>Methods</h3> This study elaborates on the findings of studies, investigating the clinical relevant increase in the HAQ-DI score, and on a study investigating the relation between disease activity, radiological damage, sociodemographic factors, and physical disability. The clinical relevant difference in physical disability (HAQ-DI) has been determined by asking patients to rate themselves relative to another patient, and was estimated to be between 0,2 and 0,3. The relation between physical disability (HAQ-DI), disease activity (DAS), and radiological damage (Modified Sharp score) was determined, using the follow-up data of 378 patients from an open prospective study of early RA (disease duration &lt; 1 year). Linear regression was used at 0, 3, 6, and 9 years after inclusion with as dependant variable the HAQ-DI, and as independent variables, disease activity (DAS), radiological damage, and sociodemographic factors. The main results of this study were that the relation between radiological progression and physical disability was dependent on the activity of the disease and the present radiological damage (5). With higher disease activity, or more damage present the effect of radiological damage on physical function decreased. Using the derived linear regression models and the measure of a clinical relevant difference in HAQ-DI a clinical relevant increase in radiological damage for the modified Sharp score was calculated. <h3>Results</h3> The clinical relevant increase in radiological damage was estimated to be about 10 or 20, for a DAS of 1 or 2 respectively. It was dependant on the activity of the disease and amount of existing joint damage. <h3>Conclusion</h3> Estimating a clinical relevant increase in radiological progression, using the patient's perspective is possible. A conservative threshold of 10–20 for a clinical relevant increase (Modified Sharp score) can be used as a guideline. These results need replication in other patient cohorts.
The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia
Authors: Tara Helen Dowling Dowling Steinsland, Stein-Erik Gullaksen, Geir Bredholt, Calum Leitch, Mireia Mayoral Safont, Øystein Bruserud, Mihaela Popa, Astri Maaland, Helen Heyerdahl, Jostein Dahle, Bjorn T. Gjertsen, Emmet Mccormack
Journal: Blood (2020)
PGE2 Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD
Authors: Xueyan Sun, Yan Su, Xiao Liu, Fengqi Liu, Gaochao Zhang, Qi Chen, Chencong Wang, Haixia Fu, Xiaolu Zhu, Kaiyan Liu, Xiaohui Zhang
Journal: Blood (2020)
COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study
Authors: Guilherme Fleury Perini, Juan Alejandro Ospina Idarraga, Maria Alejandra Torres Viera, Brady E Beltran, Denisse A. Castro, Victoria Otero, Mariana Kalmus, Lorena Fiad, Camila Peña, Henry Idrobo, Myrna Candelaria, Alana Von Glasenapp, Ivan Perdomo, Carolina Feres, Maria Prates, Sally Rose Paredes, Fernando Pérez-Jacobo, Ana Ramirez-Ibarguen, Claudia Gajardo, Macarena Alejandra Roa Salinas, Humberto Martínez Cordero, Melani Otañez, Fabiola Valvert, Efreen Montaño Figueroa, Marcos Di Stefano, Rosio Baena, Juan Antonio Choque, Virginia Abello, Ximena Valladares, Sofia Sanchez, Cristaldo Nancy, Daniela Zambrano, Juan Felipe Lasso, Andrea Noboa, Christine Rojas, Larissa LC Teixeira, Luis Malpica Castillo, Eduardo Sotomayor, Jorge J. Castillo, Luis Villela Villela
Journal: Blood (2020)
Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)
Authors: Guillermo Montalban Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, Irene Ganan-Gomez, Koji Sasaki, Kiran Naqvi, Yue Wei, Hui Yang, Kelly A. Soltysiak, Kelly S. Chien, Carlos E. Bueso-Ramos, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2020)
Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Amro Elshoury, Ashkan Emadi, Vu H. Duong, Sandrine Niyongere, Wendy Walinski, Meriem Said, Stephanie Halliwell, Kemji Eke, Kristopher Attwood, Maria R. Baer, Eunice S. Wang
Journal: Blood (2020)
In Situ Fate Mapping of Native and Stress Myelopoiesis Reveals a Unique Niche for Mono- and Dendritic Cell -Poiesis
Authors: Jizhou Zhang, Qingqing Wu, Courtney Johnson, Giang Pham, Jeremy M. Kinder, Immanuel Kwok, Keith Leong, André Olsson, Anastasiya Slaughter, Margot Lindsay May, Benjamin Weinhaus, Angelo D'Alessandro, James Douglas Engel, Jean X. Jiang, J.Matthew Koffron, Lei Huang, Lai Guang Ng, Sing Sing Way, Nathan Salomonis, H. Leighton Grimes, Daniel Lucas-Alcaraz
Journal: Blood (2020)
Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing <i>in Situ</i> Vaccination
Authors: Tanaya Shree, Sarah Haebe, Anuja Sathe, Grady Day, Debra K. Czerwinski, HoJoon Lee, Susan Grimes, Steven R. Long, Brock Martin, Hanlee Ji, Ronald Levy
Journal: Blood (2020)
Treatment Options for Newly Diagnosed Frail and Transplant-Ineligible Patients with Multiple Myeloma: A Systematic Review
Authors: Syed Maaz Abdullah, Muhammad Salman Faisal, Mohammad Ammad Ud Din, Laeth L George, Qasim Khurshid, Abdul Jabbar Dar, Karun Neupane, Amrat Ehsan, Abdul Rehman Z Zaidi, Imtisaal Waris, Mobeen Zaka Haider, Alireza Setarehaseman, Naqib Ahmad, Arsalan Babar, Hamid Ehsan, Faiz Anwer
Journal: Blood (2020)
Favourable Outcome of Non Myeloablative Allogeneic HSCT in Adult Patients with Severe Sickle Cell Disease: A Single Center Experience of 110 Patients
Authors: Mohsen Alzahrani, Bader Alahmari, Ahmed Alaskar, Ayman Hejazi, Giamal Edin Gmati, Khadega A. Abuelgasim, Hind Salama, Abdulrahman Raiza, Abdulrahman Alghamdi, Walid Mashaqbeh, Heba Alshobaki, Tahani Alanazy, Maybelle Balili, Muhammad Qureshi, Mazin Ahmed, Husam Mazin Alsadi, Moussab Damlaj
Journal: Blood (2020)
A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma
Authors: Syed Maaz Abdullah, Sikander Abdullah, Muhammad Khawar Sana, Hamid Ehsan, Syeda Aiman Gohar Naqvi, Fatima Zia Zaidi, Muhammad Tayyeb, Khadija Zia Zaidi, Mobeen Zaka Haider, Farhan Khalid, Ali Jaan, Amrat Ehsan, Talha Badar, Faiz Anwer
Journal: Blood (2020)
Real-Life Experience of Sorafenib Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML Reveals High Rates of Toxicity-Related Treatment Interruption
Authors: Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Stavroula Masouridi-Levrat, Federico Simonetta, Yves Chalandon
Journal: Blood (2020)